Search

Sergey Kaliberov Phones & Addresses

  • Concord, CA
  • Saint Louis, MO
  • 801 Castlemaine Ct, Birmingham, AL 35226 (205) 914-3622
  • 1918 Tree Top Ln, Birmingham, AL 35216 (205) 822-5908
  • 1918 Tree Top Ln #J, Birmingham, AL 35216 (205) 822-5908
  • Vestavia, AL

Resumes

Resumes

Sergey Kaliberov Photo 1

Senior Scientist

View page
Location:
Emeryville, CA
Industry:
Biotechnology
Work:
Kite Pharma A Gilead Company Dec 2017 - Mar 2020
Senior Scientist

Cell Design Labs Dec 2017 - Mar 2020
Senior Scientist

Washington University In St. Louis 2011 - Dec 2016
Research Assistant Professor

The University of Alabama at Birmingham 2002 - 2010
Research Assistant Professor
Education:
Scientific Research Institute of Molecular Biology
Doctorates, Doctor of Philosophy, Philosophy, Virology
Siberian State Medical University
Master of Science, Masters, Biophysics, Medical Biology
Siberian State Medical University
Bachelors, Bachelor of Science, Biophysics, Medical Biology
Skills:
Molecular Biology
Molecular Cloning
Virology
Vector Cloning
Gene Delivery
Cancer Research
Cell Culture
Molecular Virology
Gene Therapy
Animal Models
Cell Biology
Western Blotting
Reverse Transcription Polymerase Chain Reaction
Sds Page
Flow Cytometry
Rt Pcr
Pcr
Protein Expression
Tissue Culture
Elisa
Vector Production
Sergey Kaliberov Photo 2

Research Assistant Professor

View page
Location:
Saint Louis, MO
Industry:
Higher Education
Work:
Washington University In St. Louis
Research Assistant Professor

Business Records

Name / Title
Company / Classification
Phones & Addresses
Sergey A Kaliberov
CDEPT, LLC
INEST/HOLD/DEVELOP INTELLECTUAL PROPERTY
Alabaster, AL

Publications

Us Patents

Tumor Growth Inhibition Via Conditioning Of Tumor Microenvironment

View page
US Patent:
20110038843, Feb 17, 2011
Filed:
Mar 31, 2009
Appl. No.:
12/934665
Inventors:
Sergei A. Kusmartsev - Gainesville FL, US
Sergey Kaliberov - Birmingham AL, US
Evgeniy Eruslanov - Gainesville FL, US
Johannes W. Vieweg - Gainesville FL, US
International Classification:
A61K 35/12
A61K 31/711
C12N 15/63
C12N 5/09
A61P 35/00
US Classification:
424 9371, 514 44 R, 4353201, 435325
Abstract:
Disclosed herein are methods and materials for inhibiting tumor growth by administering viral vectors to tumor cells. Particularly exemplified herein are methods of inhibiting tumor growth of colon tumors by delivering 15-PGDH to tumor environment. Antigen presenting cells may be coadministered with 15-PGDH.

Stimulating Anti-Tumor Immune Response And Boosting Cancer Immunotherapy Via Expression Of 15-Pgdh

View page
US Patent:
20130266610, Oct 10, 2013
Filed:
Apr 1, 2013
Appl. No.:
13/854517
Inventors:
Sergei A. Kusmartsev - Gainesville FL, US
Sergey Kaliberov - Birmingham AL, US
Evgeniy Eruslanov - Gainesville FL, US
Johannes W. Vieweg - Gainesville FL, US
Assignee:
University of Florida Research Foundation, Inc. - Gaiesville FL
International Classification:
A61K 39/00
A61K 38/44
A61K 48/00
US Classification:
4241991, 4242771
Abstract:
Disclosed herein are methods and materials for inhibiting tumor growth by administering viral vectors to tumor cells. Particularly exemplified herein are methods of inhibiting tumor growth of colon tumors by delivering 15-PGDH to tumor environment. Antigen presenting cells may be coadministered with 15-PGDH.

Viral Vector Driven Mutant Bacterial Cytosine Deaminase Gene And Uses Thereof

View page
US Patent:
20070225245, Sep 27, 2007
Filed:
Apr 27, 2007
Appl. No.:
11/796574
Inventors:
Donald Buchsbaum - Alabaster AL, US
G. Gillespie - Birmingham AL, US
James Markert - Birmingham AL, US
Sergey Kaliberov - Birmingham AL, US
International Classification:
A61K 31/70
C12N 15/869
US Classification:
514044000, 435320100
Abstract:
The instant invention has developed viral vectors encoding a mutant bacterial cytosine deaminase (bCD) gene, which have a higher affinity for cytosine than wild type bCD (bCDwt). The purpose of the present invention was to evaluate cytotoxicity in vitro and therapeutic efficacy in vivo of these vectors in combination with the prodrug 5-FC and ionizing radiation against human glioma. The present study demonstrates that infection with the viral vector expressing the mutant cytosine deaminase gene resulted in increased 5-FC-mediated cell killing, compared with vectors expressing the wild-type gene. Furthermore, a significant increase in cytotoxicity following infection with viral vector expressing the mutant cytosine deaminase gene and radiation treatment of glioma cells in vitro was demonstrated as compared to infection with viral vector expressing the wild-type gene. Animal studies showed significant inhibition of subcutaneous or intracranial tumor growth of D54MG glioma xenografts by the combination of AdbCD-D314A/5-FC with ionizing radiation as compared with either agent alone, and with AdbCDwt/5-FC plus radiation. These data indicate that combined treatment with this mutant enzyme/prodrug therapy and radiotherapy provides a promising approach for cancer therapy.

Adenoviral Targeting, Compositions And Methods Therefor

View page
US Patent:
20170044269, Feb 16, 2017
Filed:
Oct 18, 2016
Appl. No.:
15/296522
Inventors:
- Saint Louis MO, US
Sergey Kaliberov - Saint Louis MO, US
International Classification:
C07K 16/30
C12N 15/86
C07K 14/005
Abstract:
Polypeptides are disclosed comprising, in N-terminal-to-C-terminal order: an N-terminal segment of Ad5 fiber tail sequence; at least 2 pseudorepeats of an Ad5 fiber shaft domain sequence; a portion of a third Ad5 fiber shaft domain sequence; a carboxy-terminal segment of a 14 fibritin bacteriophage trimerization domain sequence; a linker sequence; and a camelid single chain antibody sequence. A camelid single chain antibody sequence can be against a human carcinoembryonic antigen. Also disclosed are nucleic acids encoding these polypeptides, and adenovirus vectors comprising the polypeptides. Methods are disclosed for treating a neoplastic disease. These methods can comprise administering an adenovirus vector comprising a disclosed polypeptide. Also disclosed are methods of targeting a vector to CEA-expressing cells. These methods comprise administering an adenovirus vector comprising a disclosed polypeptide. Methods can further comprise subjecting a subject to ionizing radiation in an amount effective for inducing CEA overexpression.
Sergey A Kaliberov from Concord, CA, age ~64 Get Report